Cargando…
Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance
In March 2019 began the global pandemic COVID-19 caused by the new Coronavirus SARS-CoV-2. The first cases of SARS-CoV-2 infection occurred in November-19 in Wuhan, China. The preventive measures taken did not prevent the rapid spread of the virus to all countries around the world. To date, there ar...
Autores principales: | Ferrara, F., Vitiello, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032553/ https://www.ncbi.nlm.nih.gov/pubmed/33835386 http://dx.doi.org/10.1007/s12012-021-09649-y |
Ejemplares similares
-
Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection
por: Vitiello, Antonio, et al.
Publicado: (2022) -
Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
por: Vitiello, A., et al.
Publicado: (2021) -
ACE2/ACE imbalance and impaired vasoreparative functions of stem/progenitor cells in aging
por: Joshi, S., et al.
Publicado: (2020) -
Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19
por: Cook, Joshua R., et al.
Publicado: (2021) -
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)